Zelira Therapeutics: Launches Zenivol in Australia

  • Zelira Therapeutics (ZLD) has launched its proprietary cannabinoid medicine, Zenivol, in Australia
  • The company has received approval from the Therapeutic Goods Administration’s (TGA) Special Access Scheme to launch the treatment
  • Zenivol is for patients with chronic insomnia and will be available through Zelira’s distribution partner, Health House
  • This announcement follows a successful clinical trial conducted by the University of Western Australia
  • Zelira is on track to launch five new products across global markets in 2020
  • Company shares are up 10 per cent on the market this morning, trading for 6.6 cents per share
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

SMBC Winds Down Digital US Bank Jenius, Impacting Customers

The closure illustrates the challenges facing digital banks in the US.Highlights: SMBC announces the closure of its US...

Scammers Impersonate NAB Trade’s Tom Piotrowski to Endorse Fraudulent Investments

NAB Trade warns investors about the ongoing impersonation scams targeting clients.Highlights: Scammers are impersonating Tom Piotrowski from NAB...

Bermuda Strengthens Onchain Economy with New Regulatory Framework

Government seeks to attract blockchain innovation and investment.Highlights: Bermuda introduces new regulations to boost its onchain economy.The framework...

Australia Tightens Cash Acceptance Rules for Retailers

New regulations will impact how retailers handle cash transactions.Highlights: Australia introduces stricter cash acceptance rules for retailers.The new...